Detailed Narrative
Q4 FY25 and Full Year Performance Overview
IOL Chemicals and Pharmaceuticals reported a resilient Q4 FY25 with revenue from operations growing 4.7% year-on-year to INR528 crores. EBITDA for the quarter increased by 17% to INR67 crores, resulting in an EBITDA margin of 12.7%, a 141 basis points improvement. Profit after tax grew 12% to INR31.6 crores, with a PAT margin of 5.9%. For the full year FY25, revenue stood at INR2,079 crores, with an EBITDA of INR225 crores (11% margin) and PAT of INR101 crores (4.8% margin). Cash PAT for Q4 FY25 was INR56.4 crores, underscoring strong cash generation.
Strategic Capacity Expansion and Diversification
The company successfully commissioned a fully backward integrated Paracetamol unit with an investment of INR155 crores, funded entirely through internal accruals. This expansion has increased Paracetamol capacity to 10,800 MTPA, significantly strengthening the non-Ibu portfolio, which now contributes 34% to API revenues, up from 18% five years ago. Additionally, IOL Chemicals acquired 101 acres of land along the Chandigarh-Bathinda Highway for greenfield expansion, with necessary industrial, environmental, and NHI clearances currently underway and progressing into FY26.
API Segment Dynamics and Market Outlook
In the API segment, Ibuprofen showed improved traction in Q4 FY25 despite ongoing price challenges. Other therapeutic categories like antidiabetics, analgesics, and cardiovascular APIs (e.g., Metformin, Fenofibrate, Pantoprazole, Levetiracetam, Clopidogrel) saw stable demand. Clopidogrel capacity was expanded by 33%. While API prices, including Ibuprofen, have declined by approximately 25% over the last five years, management believes prices have bottomed out and may see improvement going forward⏳, with positive volume traction in Ibuprofen and some non-Ibu segments.
Chemical Business Performance and Margin Improvement
The chemical operations delivered stable financial performance, supported by enhanced efficiencies and better cost control. The EBITDA margin for the chemical segment improved to 6% in Q4 FY25, up from 3% in FY24. Management aims to achieve more than 6% in the current year (FY26) and eventually target 10% for the chemical sector. The merchant sale in chemicals is primarily for Ethyl Acetate, where prices have stabilized, and demand is showing increasing traction.
Focus on Export Market Expansion
IOL Chemicals is strategically focused on scaling its export revenues from the current 27% to about 40% over the medium term⏳, and specifically 40-45% for API exports within the next two years. This will be achieved by leveraging regulatory approvals (DMFs and CEPs) in key markets such as Europe, Brazil, Russia, Korea, and China for its non-Ibuprofen portfolio. The company has already received CDE approval for Ibuprofen export to China and is actively engaging with customers in this new market.
Financial Strength and Future Growth Outlook
The company maintains a strong financial foundation with a net debt to equity ratio of 0.09 at the end of FY25, reflecting minimal leverage and robust internal accruals. This provides ample headroom for funding future growth and strategic initiatives. For FY26, management expects a revenue growth of 10-15% and an EBITDA margin exceeding 15%, driven by a mix of volume and price improvements, and continued focus on operational discipline and portfolio diversification.